With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Last fall, policymakers gathered in Astana, Kazakhstan to renew their commitment to primary health care (PHC). The gathering marked the 40th anniversary of the landmark Declaration of Alma-Ata, which enshrined health as a basic human right and paved the way for global recognition of PHC as a fundamental component of national health systems.
Last month, CGD hosted four former directors of USAID’s Office of Population and Reproductive Health to reflect on their experiences, which spanned US administrations from Ronald Reagan to Barack Obama. (You can watch the event here). Below, we highlight three main takeaways— the critical role of technical leadership, the importance of data, and the need to start with the end in mind when planning for successful transitions.
Earlier this month, evidence emerged that a Nevada woman who died last September had contracted a superbug resistant to all 26 available antibiotics, including colistin, the drug of last resort. If left unchecked, antimicrobial resistance (AMR) could cause up to 10 million deaths a year by 2050 with a cumulative loss of $100 trillion to the global economy. The misuse of antibiotics in human medicine allows bacteria to evolve resistance to many life-saving drugs. But their excessive and inappropriate use in farm animals—which consume 70-80 percent of antibiotics sold in the United States—is another key factor accelerating drug resistance globally.
Health aid pays for life-saving medicines, products, and services in the poorest countries in the world. Funding for such uses needs to be smooth and uninterrupted. But when fraud is detected, funds are subject to sudden stops and starts—the result of a sequence of events set off by the scandal cycle in health aid. We examine this idea in a new CGD policy paper.